<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702936</url>
  </required_header>
  <id_info>
    <org_study_id>ILG-1</org_study_id>
    <nct_id>NCT00702936</nct_id>
  </id_info>
  <brief_title>Telmisartan Versus Ramipril After Acute Coronary Syndrome</brief_title>
  <acronym>TERACS</acronym>
  <official_title>Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the antinflammatory and endothelial progenitor cell
      (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute
      coronary syndrome
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High sensitivity C-Reactive Protein</measure>
    <time_frame>20 days after hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Progenitor Cells</measure>
    <time_frame>20 days after hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twenty-five patients assigned to ramipril 5 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twenty-five patients assigned to Telmisartan 80 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TELMISARTAN</intervention_name>
    <description>80 mg daily</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAMIPRIL</intervention_name>
    <description>5 mg daily</description>
    <arm_group_label>R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,

          -  presence of ECG ischemic changes,

          -  angiographic evidence of a primary coronary event, such as plaque erosion and/or
             rupture, fissuring, or dissection at coronary angiography,

          -  successful coronary revascularization of at least one culprit coronary vessel.

        Exclusion Criteria:

          -  Age&gt;80 years, current ACE inhibitor or ARB treatment,

          -  ejection fraction &lt;35%, infarction secondary to ischemia due to an imbalance of O2
             supply and demand,

          -  ECG abnormalities that could affect the recognition of ST segment shift,

          -  recent or chronic infective or inflammatory diseases,

          -  malignancy, and myocardial infarction,

          -  surgery or trauma in the previous month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Porto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luca Di Vito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Italo Porto, MD, PhD</last_name>
    <phone>0039(0)6-30154127</phone>
    <email>i.porto@doctors.org.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Italo Porto, MD, PhD</last_name>
    <email>italo.porto@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catholic University of the Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Italo Porto, MD, PhD</last_name>
      <email>i.porto@doctors.org.uk</email>
    </contact>
    <contact_backup>
      <last_name>Luca Di Vito, MD</last_name>
      <email>divitoluca@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Italo Porto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Di Vito, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.rm.unicatt.it</url>
    <description>Catholic University</description>
  </link>
  <reference>
    <citation>Biasucci LM, Lombardi M, Piro M, Di Giannuario G, Liuzzo G, Crea F. Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Heart. 2005 May;91(5):670-1.</citation>
    <PMID>15831660</PMID>
  </reference>
  <results_reference>
    <citation>Liakishev AA. [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial]. Kardiologiia. 2008;48(5):72. Russian.</citation>
    <PMID>18537808</PMID>
  </results_reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <last_update_submitted>June 19, 2008</last_update_submitted>
  <last_update_submitted_qc>June 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Catholic University of the Sacred Heart</name_title>
    <organization>Catholic University of the Sacred Heart</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

